Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multiple-dose IV SYNT001 study in healthy volunteers
NL-OMON45830Phase 1Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of orilanolimab in autoimmune disease and Blistering disease (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Safety and tolerability and Pharmacokinetics of SYNT001. Started Nov 2018; status: active, not recruiting.
02
Drugs
orilanolimab
03
Conditions
autoimmune diseaseBlistering disease
Beyond the preview
Go deeper on NL-OMON45830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45830.